More Than a Partnership: How Oncogene-Driven Patient Groups Are Mobilizing the Global Community to Drive Research
Upal Basu RoyIt has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way […] Read more
Veterans Health Administration’s Lung Precision Oncology Program Helps Individualize Treatment
Michael Kelley+more
Lung cancer is not only the leading cause of cancer deaths in the United States, with nearly 229,000 people diagnosed annually, but is also the deadliest cancer affecting patients of […] Read more
Awareness-raising Bike Ride in The Netherlands Connected Hospitals, Patients
Ilima LoomisPatients and supporters cycled nearly 1,150 kilometers through The Netherlands on May 21, 2021 in a “White Ribbon Tour” to raise awareness for lung cancer. The grassroots event was organized […] Read more
Anne Katz, PhD, RN, FAAN, is a certified sexuality counselor and clinical nurse specialist at Cancer Care Manitoba, Winnipeg, Canada, and the author of multiple books on cancer survivorship. In the following article, Dr. Katz discusses lung cancer survivorship challenges as well as considerations that providers should take... Read more
Lung Cancer Health Care Delivery, Community Building, and Research: Are They Truly Inclusive?
Jill Feldman, MA+more
Lung cancer was first identified as a distinct disease in 1761.1 Since this discovery, we have come a long way—both in terms of progress towards understanding the heterogeneous biology of […] Read more
Ending Stigma in Lung Cancer: The IASLC Participates in a Collaborative Summit Held by the National Lung Cancer Roundtable
Jill Feldman, MA+more
Stigma is any thinking or behavior that produces internal shame or external judgment toward a person, place, or thing.1 In healthcare, stigma could be any sociocultural norm that prevents a […] Read more
Disrupting the Paradigm: Partnering With Oncogene-Focused Patient Groups to Propel Research
Upal Basu RoyGenomic alterations drive more than 60% of adenocarcinoma cases of NSCLC.1 Approximately 25% of these cases will have an oncogenic driver (EGFR, ALK, ROS1, BRAF, or NTRK) that can be […] Read more
By Leah Lawrence Posted: December 11, 2019 Many patients newly diagnosed with lung cancer have difficulty navigating the world of cancer when unexpectedly and unwillingly thrust into it. In addition […] Read more
STARS Patient Research Advocate Training Program Seeks Patients and Caregivers
By Adam Mohrbacher Posted: December 11, 2019 Patients with lung cancer and their caregivers are becoming more empowered and knowledgeable than ever. As a result, lung cancer now has a […] Read more
From Patient to Patient Research Advocate: The STARS Journey
By Adam Mohrbacher Posted: December 11, 2019 With the rise of organized lung cancer patient advocacy groups,1 patients, advocates, and caregivers are now playing a larger role than ever in […] Read more